Cartesian Therapeutics (NASDAQ:RNAC) Releases Earnings Results, Beats Expectations By $1.35 EPS

Cartesian Therapeutics (NASDAQ:RNACGet Free Report) released its quarterly earnings data on Thursday. The company reported $0.54 earnings per share for the quarter, topping the consensus estimate of ($0.81) by $1.35, Zacks reports. The firm had revenue of $33.45 million for the quarter, compared to the consensus estimate of $6.00 million.

Cartesian Therapeutics Stock Up 3.9 %

Shares of NASDAQ:RNAC traded up $0.50 during mid-day trading on Friday, reaching $13.37. 49,521 shares of the stock were exchanged, compared to its average volume of 111,382. The stock’s 50 day simple moving average is $21.35 and its 200-day simple moving average is $21.34. Cartesian Therapeutics has a one year low of $11.66 and a one year high of $42.60.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. HC Wainwright reduced their price target on shares of Cartesian Therapeutics from $54.00 to $49.00 and set a “buy” rating on the stock in a research report on Wednesday, July 3rd. Needham & Company LLC reduced their target price on Cartesian Therapeutics from $42.00 to $41.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partnrs restated an “outperform” rating on shares of Cartesian Therapeutics in a report on Tuesday, April 23rd. TD Cowen started coverage on Cartesian Therapeutics in a research report on Tuesday, August 6th. They set a “buy” rating on the stock. Finally, Oppenheimer lowered Cartesian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.67.

Read Our Latest Stock Report on RNAC

Cartesian Therapeutics Company Profile

(Get Free Report)

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.

Featured Articles

Earnings History for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.